Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.

Lung cancer (Amsterdam, Netherlands) - 1 May 2016

Doesch Janine, Debus Dirk, Meyer Christian, Papadopoulos Thomas, Schultz Erwin S, Ficker Joachim H, Brueckl Wolfgang M

Abstract excerpt

INTRODUCTION: Afatinib is a tyrosine kinase inhibitor (TKI), that has been approved for treating patients with epidermal growth factor receptor (EGFR) mutated advanced non-small-cell lung cancer (NSCLC). Stevens-Johnson syndrome (SJS) related to EGFR directed TKIs is a rare adverse event. CASE PRESENTATION: We report a case of a 79-year-old white female with EGFR-mutated, metastatic non-small-cell lung cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adrenal Cortex Hormones
Share to Afatinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Lung Neoplasms

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Stevens-Johnson Syndrome

Source

Identifiers

PMID: 27040849
DOI: 10.1016/j.lungcan.2016.02.015

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Afatinib-associated Stevens-Johnson syndrome in an EGFR-mutated lung cancer patient.PMID 27040849Read ↗

Successful erlotinib rechallenge in an EGFR-mutant metastatic non-small cell lung cancer patient with afatinib-induced drug rash with eosinophilia and systemic symptoms: A case report.Semantic proximity Read ↗

Drug-induced Hypersensitivity Syndrome by EGFR-TKI in a Patient with Lung Cancer.Semantic proximity Read ↗

Osimertinib tolerance in a patient with Stevens Johnson Syndrome during Osimertinib treatment followed by PembrolizumabSemantic proximity Read ↗

Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.Semantic proximity Read ↗

Unusual Adverse Events in a Patient With BRAF-Mutated Non-Small Cell Lung Cancer Treated With BRAF/MEK Inhibition.Semantic proximity Read ↗

Osimertinib-Associated Toxic Epidermal Necrolysis in a Lung Cancer Patient Harboring an EGFR Mutation-A Case Report and a Review of the Literature.Semantic proximity Read ↗

Management of epidermal growth factor receptor tyrosine kinase inhibitor-related cutaneous and gastrointestinal toxicities.Semantic proximity Read ↗

Successful Use of Afatinib After Erlotinib-induced Pneumonitis in a Patient With Epidermal Growth Factor Receptor-mutant Lung Cancer.Semantic proximity Read ↗

Association between dermatologic adverse events and quality of life in lung cancer patients treated with epidermal growth factor receptor-tyrosine kinase inhibitors.Semantic proximity Read ↗

Minocycline prevents and repairs the skin disorder associated with afatinib, one of the epidermal growth factor receptor-tyrosine kinase inhibitors for non-small cell lung cancerSemantic proximity Read ↗

Osimertinib-Induced Toxic Epidermal Necrolysis - A Case Report.Semantic proximity Read ↗

[Toxicity associated with EGRF inhibition: review and key aspects in the management of afatinib].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.